164 related articles for article (PubMed ID: 26687594)
21. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
Stansfield LC; Pollyea DA
Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
[TBL] [Abstract][Full Text] [Related]
22. First new drug approval for AML in 15 years.
Sheridan C
Nat Biotechnol; 2017 Aug; 35(8):696-698. PubMed ID: 28787411
[No Abstract] [Full Text] [Related]
23. American Society of Hematology--48th Annual Meeting and Exposition. 9-12 December 2006, Orlando, FL, USA.
Walker K
IDrugs; 2007 Feb; 10(2):75-7. PubMed ID: 17285451
[No Abstract] [Full Text] [Related]
24. First Approved Kinase Inhibitor for AML.
Rasko JEJ; Hughes TP
Cell; 2017 Nov; 171(5):981. PubMed ID: 29149610
[TBL] [Abstract][Full Text] [Related]
25. Bis(1H-indol-2-yl)methanones are effective inhibitors of FLT3-ITD tyrosine kinase and partially overcome resistance to PKC412A in vitro.
Heidel F; Lipka DB; Mirea FK; Mahboobi S; Grundler R; Kancha RK; Duyster J; Naumann M; Huber C; Böhmer FD; Fischer T
Br J Haematol; 2009 Mar; 144(6):865-74. PubMed ID: 19183186
[TBL] [Abstract][Full Text] [Related]
26. [Pathophysiology and treatment of acute myeloid leukemia].
Naoe J
Rinsho Ketsueki; 2003 Apr; 44(4):219-26. PubMed ID: 12784654
[No Abstract] [Full Text] [Related]
27. New Models of Therapy: When Acute Leukemia Becomes Chronic.
Ustun C; Stone R; Weisdorf D
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1856-7. PubMed ID: 26183079
[No Abstract] [Full Text] [Related]
28. [Current status and future perspectives of the Glivec Registration System established by JSCH/JSH-TARGET].
Kizaki M;
Rinsho Ketsueki; 2007 Jun; 48(6):468-74. PubMed ID: 17633094
[No Abstract] [Full Text] [Related]
29. Synergistic effect of all‑trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells.
Chi HT; Ly BT; Vu HA; Sato Y; Dung PC; Xinh PT
Mol Med Rep; 2015 May; 11(5):3969-75. PubMed ID: 25592076
[TBL] [Abstract][Full Text] [Related]
30. Alisertib: a new option for acute myeloid leukaemia.
Thomas X
Lancet Haematol; 2020 Feb; 7(2):e87-e88. PubMed ID: 31837958
[No Abstract] [Full Text] [Related]
31. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.
Chevallier P; Prebet T; Pigneux A; Hunault M; Delaunay J; Perry F; Lode L; Richebourg S; Blanchet O; Vey N; Ifrah N; Milpied N; Blaise D; Harousseau JL; Mohty M
Leukemia; 2010 Feb; 24(2):467-9. PubMed ID: 19847200
[No Abstract] [Full Text] [Related]
32. American Society of Hematology--50th Annual Meeting and Exposition--Part 2.
Cleverley J; Millar E
IDrugs; 2009 Feb; 12(2):66-8. PubMed ID: 19216125
[No Abstract] [Full Text] [Related]
33. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Goldman JM; Melo JV
N Engl J Med; 2001 Apr; 344(14):1084-6. PubMed ID: 11287980
[No Abstract] [Full Text] [Related]
34. Report from the 34th annual meeting of the American Society of Hematology, December 4-8, 1992.
Markman M
J Cancer Res Clin Oncol; 1993; 119(11):695-6. PubMed ID: 8349726
[No Abstract] [Full Text] [Related]
35. Highlights from the 46 th annual meeting of the American Society of Hematology.
Fassas A; Barlogie B; Feusner J; Kay NE; Wingard JR
Clin Adv Hematol Oncol; 2005 Feb; 3(2):111-6. PubMed ID: 16166978
[No Abstract] [Full Text] [Related]
36. FLT3 inhibitors for acute myeloid leukemia.
Lancet JE
Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
[No Abstract] [Full Text] [Related]
37. The role of alisertib in treatment of peripheral T-cell lymphomas.
Gallop-Evans E
Future Oncol; 2015 Sep; 11(18):2515-24. PubMed ID: 26344156
[TBL] [Abstract][Full Text] [Related]
38. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
Scholl S; Spies-Weisshart B; Klink A; Muegge LO; Fricke HJ; Hochhaus A
Ann Hematol; 2011 Apr; 90(4):473-5. PubMed ID: 20652568
[No Abstract] [Full Text] [Related]
39. Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Swords R; Freeman C; Giles F
Leukemia; 2012 Oct; 26(10):2176-85. PubMed ID: 22614177
[TBL] [Abstract][Full Text] [Related]
40. Minor BCR-ABL1-Positive Acute Myeloid Leukemia Associated With the NPM1 Mutation and FLT3 Internal Tandem Duplication.
Kim MJ; Ahn S; Jeong SH; Jang JH; Han JH; Choi JR; Cho SR
Ann Lab Med; 2016 May; 36(3):263-5. PubMed ID: 26915617
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
